Bulgaria vs Burkina Faso: Number of clinical trials
Bulgaria
16 trials
in 2024
Burkina Faso
13 trials
in 2024
Bulgaria rank
61st
Burkina Faso rank
63rd
Number of clinical trials over time
- Bulgaria
- Burkina Faso
How they compare
Bulgaria currently reports 16 trials against 13 trials in Burkina Faso, a difference of 3 trials.
That makes Bulgaria's figure about 1.2 times Burkina Faso's.
The two have swapped places 3 times across 20 shared years of data; in 2005 it was Burkina Faso ahead.
Bulgaria ranks 61st and Burkina Faso ranks 63rd of 153 countries.
Bulgaria has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bulgaria | Burkina Faso | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.6 trials | 4 trials | 1.6 trials | Bulgaria |
| 2010s | 10.6 trials | 6.3 trials | 4.3 trials | Bulgaria |
| 2020s | 18.4 trials | 9.6 trials | 8.8 trials | Bulgaria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher number of clinical trials, Bulgaria or Burkina Faso?
- Bulgaria, at 16 trials against 13 trials in Burkina Faso as of 2024.
- What is the difference in number of clinical trials between Bulgaria and Burkina Faso?
- 3 trials, with Bulgaria ahead.
- How many years of comparable data are there for Bulgaria and Burkina Faso?
- 20 years are reported by both, from 2005 to 2024.
- How do Bulgaria and Burkina Faso rank globally for number of clinical trials?
- Bulgaria ranks 61st and Burkina Faso ranks 63rd of 153 countries.
- Where does this data come from?
- ClinicalTrials.gov (2025) β with major processing by Our World in Data, published as Number of clinical trials. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Annual number of completed clinical trials registered in the ClinicalTrials.gov database for each country. Registration in the ClinicalTrials database is mandatory for trials in the United States, but voluntary for other countries.